查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1585655

生物製药 CMO/CRO 市场：供应商、服务类型、产品类型、业务规模、治疗应用 - 2025-2030 年全球预测

Biopharmaceutical CMO & CRO Market by Source (Mammalian, Non-Mammalian), Service Type (Contract Manufacturing, Contract Research), Product, Scale of Operation, Therapeutic Applications - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年生物製药CMO/CRO市场规模为813.2亿美元，预计2024年将达到956.5亿美元，2030年将成长至2,606.5亿美元，复合年增长率为18.10%。

生物製药委外研发机构（CMO）和委外研发机构（CRO）市场是药物开发和製造连续体不可分割的一部分，推动药物创新，同时缓解成本和产能限制。 CMO 提供从临床前开发到商业生产的製造服务，而 CRO 提供研究服务，利用专业知识和分析工具加速开发新药。随着製药公司在高度法规环境中努力缩短上市时间，这种共生关係变得越来越必要。应用包括生技药品、生物相似药、小分子和个人化医疗，最终用途产业从治疗到疫苗。主要成长要素包括慢性病的流行、生技药品和生物相似药的进步、政府激励措施以及寻求保持市场竞争力同时降低营运风险和成本的製药公司的外包趋势。最新的机会在于寻求与 CMO/CRO 合作以获得利基技能和能力的生物技术新兴企业的激增，以及新兴市场对临床试验的需求不断增长。然而，市场面临复杂的监管环境、智慧财产权和品质保证问题等挑战，这些挑战往往限制无缝成长和扩充性。此外，市场也受到高度竞争格局和对技术纯熟劳工的需求的影响，这使业务运作变得复杂。在利用人工智慧和机器学习优化流程、增强药物开发和製造过程中资料主导的决策以及透过连续製造提高效率等领域，创新和研究的机会比比皆是。企业可以透过投资强大的品质源于设计 (QbD) 框架和资料分析来加强合规性并缩短时间，从而受益。该市场的特点是技术快速进步、竞争激烈和监管审查，使得业务敏捷性和适应性对于持续成长至关重要。

主要市场统计
基准年[2023] 813.2亿美元
预测年份 [2024] 956.5亿美元
预测年份 [2030] 2606.5亿美元
复合年增长率（%） 18.10%

市场动态：针对快速发展的生物製药 CMO/CRO 市场揭示的关键市场洞察

由于供需的动态互动，生物製药 CMO/CRO 市场正在经历转型。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 製药和生技领域外包需求不断成长
    • 聚合物治疗的潜在需求
    • 生物製药领域的持续研发活动
  • 市场限制因素
    • 与外包公司较少和竞争较少有关的问题
  • 市场机会
    • 先进技术在生物技术领域的渗透
    • 用于标靶治疗的细胞和基因疗法的出现
  • 市场挑战
    • CMO 和 CRO课责和品管问题

波特的五力：驾驭生物製药 CMO/CRO 市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解生物製药CMO/CRO市场的外部影响

外部宏观环境因素在塑造生物製药 CMO/CRO 市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解生物製药 CMO/CRO 市场竞争状况

生物製药 CMO/CRO 市场的详细市场占有率分析提供了对供应商绩效的全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 生物製药 CMO/CRO 市场中的定位矩阵供应商绩效评估

FPNV定位矩阵是评估生物製药CMO/CRO市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议 规划生物製药 CMO/CRO 市场的成功之路

生物製药 CMO/CRO 市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 製药和生技领域对外包服务的需求不断增加。
      • 聚合物治疗的潜在需求
      • 生物製药领域持续的研发活动
    • 抑制因素
      • 与外包供应商减少和竞争减少相关的问题
    • 机会
      • 尖端技术在生物技术领域的渗透
      • 用于标靶治疗的细胞和基因疗法的出现
    • 任务
      • CMO 和 CRO课责和品管问题
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 生物製药 CMO/CRO 市场：依来源分类

  • 哺乳动物的
  • 非哺乳动物

第七章生物製药CMO/CRO市场：依服务类型

  • 契约製造
  • 委託研究

第八章生物製药 CMO/CRO 市场：副产品

  • 生物製药
  • 生物相似药

第九章依业务规模分類的生物製药 CMO/CRO 市场

  • 临床
  • 商业的

第十章 生物製药CMO/CRO市场处理申请

  • 心血管疾病
  • 感染疾病
  • 神经病学
  • 肿瘤学
  • 眼科
  • 呼吸系统疾病

第十一章美洲生物製药CMO/CRO市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太生物製药CMO/CRO市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲生物製药CMO/CRO市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie, Inc.
  • arexel International Corporation
  • Baxter International Inc.
  • Boehringer Ingelheim Biopharmaceuticals GmbH
  • Boehringer Ingelheim GmbH
  • Catalent, Inc.
  • Charles River Laboratories International, Inc.
  • Eurofins Scientific Limited
  • FUJIFILM Diosynth Biotechnologies USA, Inc.
  • ICON Plc
  • KBI Biopharma, Inc.
  • KEMWELL BIOPHARMA PRIVATE LIMITED
  • Laboratory Corporation of America Holdings
  • Lonza Group AG
  • NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC
  • Patheon Inc.
  • Rentschler Biopharma SE
  • Sterling Pharma Solutions
Product Code: MRR-3A2E844FDA5E

The Biopharmaceutical CMO & CRO Market was valued at USD 81.32 billion in 2023, expected to reach USD 95.65 billion in 2024, and is projected to grow at a CAGR of 18.10%, to USD 260.65 billion by 2030.

The biopharmaceutical Contract Manufacturing Organization (CMO) and Contract Research Organization (CRO) markets have become essential in the drug development and manufacturing continuum, propelling pharmaceutical innovations while mitigating costs and capacity constraints. CMOs provide manufacturing services that range from pre-clinical development to commercial production, while CROs offer research services to aid clients in accelerating the development of new drugs through specialized knowledge and analytical tools. This symbiotic relationship is increasingly necessary as pharmaceutical companies strive to expedite time-to-market amidst stringent regulatory environments. The application scope includes biologics, biosimilars, small molecules, and personalized medicine, with end-use industries spanning therapeutics to vaccines. Key growth influencers include the rising prevalence of chronic diseases, advancements in biologics and biosimilars, governmental incentives, and the outsourcing trend by pharmaceutical companies eager to retain market competitiveness while lowering operational risks and costs. The latest opportunities lie in the surge of biotechnology startups seeking partnerships with CMOs/CROs for niche skill sets and capabilities, and the growing demand for clinical trials across emerging markets. Nevertheless, the market grapples with challenges such as complex regulatory landscapes, intellectual property concerns, and quality assurance issues, which often constrain seamless growth and scalability. Additionally, the market is impacted by high competition and the need for skilled labor, which complicate the operational landscapes. Innovation and research opportunities abound in areas like process optimization using artificial intelligence and machine learning, enhancing data-driven decision-making in drug development and manufacturing processes, and increasing efficiency through continuous manufacturing. Companies can benefit from investing in robust Quality by Design (QbD) frameworks and data analytics to enhance compliance and accelerate timelines. The market is characterized by rapid technological advancements, competitive collaboration, and regulatory scrutiny, making business agility and adaptability crucial for sustained growth.

KEY MARKET STATISTICS
Base Year [2023] USD 81.32 billion
Estimated Year [2024] USD 95.65 billion
Forecast Year [2030] USD 260.65 billion
CAGR (%) 18.10%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Biopharmaceutical CMO & CRO Market

The Biopharmaceutical CMO & CRO Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising need for outsourced service in pharmaceutical and biotechnology sector
    • Potential demand for macromolecular therapeutics
    • Ongoing research and development activities in biopharmaceutical sector
  • Market Restraints
    • Issues pertinent to fewer outsource suppliers and less competition
  • Market Opportunities
    • Penetration of advanced technology in the biotechnology field
    • Emergence of Cell and Gene Therapies for Targeted Treatment
  • Market Challenges
    • Concern associated with accountability and quality control of CMO and CRO

Porter's Five Forces: A Strategic Tool for Navigating the Biopharmaceutical CMO & CRO Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Biopharmaceutical CMO & CRO Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Biopharmaceutical CMO & CRO Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Biopharmaceutical CMO & CRO Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Biopharmaceutical CMO & CRO Market

A detailed market share analysis in the Biopharmaceutical CMO & CRO Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Biopharmaceutical CMO & CRO Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Biopharmaceutical CMO & CRO Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Biopharmaceutical CMO & CRO Market

A strategic analysis of the Biopharmaceutical CMO & CRO Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Biopharmaceutical CMO & CRO Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc., arexel International Corporation, Baxter International Inc., Boehringer Ingelheim Biopharmaceuticals GmbH, Boehringer Ingelheim GmbH, Catalent, Inc., Charles River Laboratories International, Inc., Eurofins Scientific Limited, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., ICON Plc, KBI Biopharma, Inc., KEMWELL BIOPHARMA PRIVATE LIMITED, Laboratory Corporation of America Holdings, Lonza Group AG, NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC, Patheon Inc., Rentschler Biopharma SE, and Sterling Pharma Solutions.

Market Segmentation & Coverage

This research report categorizes the Biopharmaceutical CMO & CRO Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Source, market is studied across Mammalian and Non-Mammalian.
  • Based on Service Type, market is studied across Contract Manufacturing and Contract Research.
  • Based on Product, market is studied across Biologics and Biosimilars.
  • Based on Scale of Operation, market is studied across Clinical and Commercial.
  • Based on Therapeutic Applications, market is studied across Cardiovascular Diseases, Infectious Disease, Neurology, Oncology, Ophthalmology, and Respiratory Disorder.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising need for outsourced service in pharmaceutical and biotechnology sector
      • 5.1.1.2. Potential demand for macromolecular therapeutics
      • 5.1.1.3. Ongoing research and development activities in biopharmaceutical sector
    • 5.1.2. Restraints
      • 5.1.2.1. Issues pertinent to fewer outsource suppliers and less competition
    • 5.1.3. Opportunities
      • 5.1.3.1. Penetration of advanced technology in the biotechnology field
      • 5.1.3.2. Emergence of Cell and Gene Therapies for Targeted Treatment
    • 5.1.4. Challenges
      • 5.1.4.1. Concern associated with accountability and quality control of CMO and CRO
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Biopharmaceutical CMO & CRO Market, by Source

  • 6.1. Introduction
  • 6.2. Mammalian
  • 6.3. Non-Mammalian

7. Biopharmaceutical CMO & CRO Market, by Service Type

  • 7.1. Introduction
  • 7.2. Contract Manufacturing
  • 7.3. Contract Research

8. Biopharmaceutical CMO & CRO Market, by Product

  • 8.1. Introduction
  • 8.2. Biologics
  • 8.3. Biosimilars

9. Biopharmaceutical CMO & CRO Market, by Scale of Operation

  • 9.1. Introduction
  • 9.2. Clinical
  • 9.3. Commercial

10. Biopharmaceutical CMO & CRO Market, by Therapeutic Applications

  • 10.1. Introduction
  • 10.2. Cardiovascular Diseases
  • 10.3. Infectious Disease
  • 10.4. Neurology
  • 10.5. Oncology
  • 10.6. Ophthalmology
  • 10.7. Respiratory Disorder

11. Americas Biopharmaceutical CMO & CRO Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Biopharmaceutical CMO & CRO Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Biopharmaceutical CMO & CRO Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie, Inc.
  • 2. arexel International Corporation
  • 3. Baxter International Inc.
  • 4. Boehringer Ingelheim Biopharmaceuticals GmbH
  • 5. Boehringer Ingelheim GmbH
  • 6. Catalent, Inc.
  • 7. Charles River Laboratories International, Inc.
  • 8. Eurofins Scientific Limited
  • 9. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
  • 10. ICON Plc
  • 11. KBI Biopharma, Inc.
  • 12. KEMWELL BIOPHARMA PRIVATE LIMITED
  • 13. Laboratory Corporation of America Holdings
  • 14. Lonza Group AG
  • 15. NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC
  • 16. Patheon Inc.
  • 17. Rentschler Biopharma SE
  • 18. Sterling Pharma Solutions

LIST OF FIGURES

  • FIGURE 1. BIOPHARMACEUTICAL CMO & CRO MARKET RESEARCH PROCESS
  • FIGURE 2. BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. BIOPHARMACEUTICAL CMO & CRO MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. BIOPHARMACEUTICAL CMO & CRO MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BIOPHARMACEUTICAL CMO & CRO MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BIOPHARMACEUTICAL CMO & CRO MARKET DYNAMICS
  • TABLE 7. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY NON-MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CONTRACT MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CONTRACT RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOSIMILARS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CLINICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RESPIRATORY DISORDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 235. BIOPHARMACEUTICAL CMO & CRO MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 236. BIOPHARMACEUTICAL CMO & CRO MARKET, FPNV POSITIONING MATRIX, 2023